News

From our CEO

25 February 2026

Rohan Greenland The May 50K

The red coats are coming to Parliament House next week, but it has nothing to do with the 250th anniversary of US independence.

MS Australia will join the Parliamentary Friends of Multiple Sclerosis Group and guests to do three important things.

First, we will be announcing the outcomes of the annual MSA research grant rounds, continuing our deep and abiding commitment to fund the best possible research to treat, prevent and ultimately cure MS. This continued investment is only made possible by the generosity of our many donors, our hard-working MS Member Organisations, our corporate sponsors, and all those who participate in critically important fundraising events such as the forthcoming May 50K.

Second, we will be celebrating the contribution that MS researchers make to the global quest to propel us faster and further down the pathways to cures, wearing red lab coats to make a visible statement about the importance of their work.

Third, we will be highlighting the need for continued government investment in health and medical research, particularly through the Medical Research Future Fund (MRFF). In particular, MSA is calling for a ten-year Neurological Research Mission to be funded through the MRFF. The robust case for a Research Mission has been set out in both the MSA and Neurological Alliance Australia’s Federal Budget submissions.

Our speakers in Canberra will include two deeply committed parliamentarians, the long-serving Co-Chairs of the Parliamentary Friends of MS Group, Senators Deborah O’Neill and Wendy Askew.

We will also hear from Renee Coffey MP, who lives with MS and was elected to represent the people of Griffith in Brisbane at the last election.

And a paediatric neurologist, Dr Monique Ryan, the Member for Kooyong, will speak about her support for the campaign to release full funding for medical research from the MRFF.

We are looking forward to a big day in Canberra next Wednesday when the red coats come to town.

Related News

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

MS News

PBS access to two vital MS treatments under threat as Government decision looms

1 July 2026

Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

From our CEO